Joseph Sabik of the Cleveland Clinic, Cleveland, Ohio, considers whether the SYNTAX trial changed cardiology and cardiothoracic surgery practice in the United States.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Cardiac
March 28, 2016
This video demonstrates a bypass procedure of the ramus interventricularis anterior artery through an 8 cm incision in the middle of the lower third of the sternum.
March 28, 2016
A refreshing , adequately supported by pragmatic imaging, 22 minute presentation from an Arizona meeting that many surgeons would find quite informative and educating. Dr.
March 27, 2016
Norepinephrine is often used to maintain the mean pressure during open heart surgery but it is said that it could constrict cerebral arteries, reducing cerebral blood flow. Is it true? The authors explored the association of Norepi doses and rSO2 measured using near-infrared spectroscopy.
March 27, 2016
Therapy with b-blockers has shown a beneficial effect in reducing aortic dilation progression and has been proposed as the standard treatment for Marfan´s syndrome (MFS). However, angiotensin II-receptor blockers are emerging as potential alternatives to b-blockers.
March 25, 2016
An overview of the basic pharmacology of commonly used cardiovascularly active drugs.
March 24, 2016
For you chocolate lovers out there, hard evidence that dark chocolate can boost endurance performance.
March 23, 2016
Robert Bartlett, Emeritus Professor of Surgery at the University of Michigan Medical Center, Ann Arbor, Michigan, presents an informative talk on extracorporeal membrane oxygenation (ECMO).
March 23, 2016
Guidelines recommend that ICDs should not be implanted until after 90 days following revascularization in patients with an EF<35% and an MI. Studies have shown that no clinical benefit or detriment was derived by implantation prior to 90 days.
March 22, 2016
In this study the STS/ACC Transcatheter Valve Therapy registry was used to compare TAVI in nonogenarians versus TAVI in patients <90 years old. In total 3,773 (15.7%) of the patients were >90 years old. Mortality at 30 days and 1-year was significantly higher for nonogenarians (8.8% vs. 5.9%, p<0.001 and 24.8% vs.